Skye Bioscience (SKYE)

• Market cap: $82.8M
• 1 day: -2.50%
• 5 days: -16.00%
• 1 month: -16.77%
• 3 months: -33.25%
• 6 months: -56.67%
• Year to date: -4.21%
• 1 year: -78.49%
• 5 years: -78.49%
• 10 years: -78.49%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Employees: 11

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

214% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 7

100% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 10

47% more call options, than puts

Call options by funds: $87K | Put options by funds: $59K

16% more funds holding

Funds holding: 62 [Q2] → 72 (+10) [Q3]

7.19% less ownership

Funds ownership: 92.04% [Q2] → 84.84% (-7.19%) [Q3]

51% less capital invested

Capital invested by funds: $207M [Q2] → $101M (-$106M) [Q3]

60% less funds holding in top 10

Funds holding in top 10: 5 [Q2] → 2 (-3) [Q3]